{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:30:29Z","timestamp":1761093029711,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.urolonc.2020.08.026","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T01:44:12Z","timestamp":1600134252000},"page":"194.e9-194.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Naoki","family":"Fujita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Momota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tobisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.urolonc.2020.08.026_bib0001","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/iju.14082","article-title":"Predictive biomarkers for drug response in bladder cancer","volume":"26","author":"Yoshida","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2020.08.026_bib0002","article-title":"Preoperative chronic kidney disease predicts poor prognosis in patients with primary non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor","author":"Fujita","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.08.026_bib0003","article-title":"Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor","author":"Fujita","year":"2020","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.026_bib0004","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.026_bib0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.08.026_bib0006","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bju.14915","article-title":"Update on the guideline of guidelines: non-muscle-invasive bladder cancer","volume":"125","author":"Taylor","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.08.026_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.03.009","article-title":"Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guerin in patients with high-risk non-muscle-invasive bladder cancer","author":"Fujita","year":"2020","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.026_bib0008","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.urolonc.2020.08.026_bib0009","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0022-5347(17)69643-5","article-title":"Cytology of the urine sediment in neoplasms of the urinary tract","volume":"57","author":"Papanicolaou","year":"1947","journal-title":"J Urol"},{"issue":"28","key":"10.1016\/j.urolonc.2020.08.026_bib0010","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.026_bib0011","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1177\/0962280215584401","article-title":"The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes","volume":"26","author":"Austin","year":"2017","journal-title":"Stat Methods Med Res"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.026_bib0012","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.08.026_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001768.pub3","article-title":"Follow-up strategies for women treated for early breast cancer","author":"Moschetti","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urolonc.2020.08.026_bib0014","article-title":"Follow-up strategies for patients treated for non-metastatic colorectal cancer","volume":"9","author":"Jeffery","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.026_bib0015","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2010.05.041","article-title":"Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution?","volume":"58","author":"Giannarini","year":"2010","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.026_bib0016","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.juro.2011.07.005","article-title":"Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival","volume":"186","author":"Boorjian","year":"2011","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.026_bib0017","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12032-017-0955-9","article-title":"Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer","volume":"34","author":"Kusaka","year":"2017","journal-title":"Med Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.026_bib0018","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s12032-018-1152-1","article-title":"Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma","volume":"35","author":"Iwamura","year":"2018","journal-title":"Med Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2020.08.026_bib0019","doi-asserted-by":"crossref","first-page":"8746","DOI":"10.18632\/oncotarget.23982","article-title":"Detecting asymptomatic recurrence after radical nephroureterectomy contributes to better prognosis in patients with upper urinary tract urothelial carcinoma","volume":"9","author":"Horiguchi","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.urolonc.2020.08.026_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \"Primary\" and \"Secondary\" muscle-invasive bladder cancer as a basis for disparate outcomes to Cisplatin-based Neoadjuvant Chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.08.026_bib0021","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/j.clgc.2019.01.007","article-title":"Determinants of guideline-based treatment in patients with cT1 Bladder cancer","volume":"17","author":"Balakrishnan","year":"2019","journal-title":"Clin Genitourin Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:45Z","timestamp":1761041985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1078143920303951"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.026","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}